TIK-101 (dCS) - NMDA partial agonist with initial indication targets in anxiety disorders, and a potential to cause a paradigm shift in the approach to psychotherapy.
TIK-201(NaPB) - HDAC inhibitor whose initial indication is Spinal Muscular Atrophy with label expansions to ALS and MS.
Tikvah Therapeutics acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs relating to the central nervous system - neurology and psychiatry.
